NasdaqGM:SMMTBiotechs
Assessing Summit Therapeutics (SMMT) Valuation After Ivonescimab Phase III Data At Major Oncology Conference
Why ivonescimab data at ELCC 2026 matters for Summit Therapeutics (SMMT)
Summit Therapeutics (SMMT) drew investor attention after presenting new clinical data for its investigational bispecific antibody, ivonescimab, at the 2026 European Lung Cancer Congress in Copenhagen.
The update covered multiple Phase III trials in non small cell lung cancer and colorectal cancer, providing new information on the progress of Summit’s late stage pipeline and how that progress may relate to the current...